Anales de la RANM

50 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 LINFOMA NO HODGKIN FOLICULAR Fernández-Rañada de la Gándara JM An RANM. 2025;142(01): 41 - 50 22. Arranz R, García-Alfonso P, Sobrino P, et al. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non- Hodgkin's lymphoma: results from a pros- pective, multicenter trial with double rando- mization. Journal of Clinical Oncology. 1998; 16:1538-1546. 23. Luminari S, Manni M, Galimberti S, et al. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lym- phoma: The FOLL12 Study. J Clin Oncol. 2022; 40:729-739. 24. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma respon- ding to rituximab plus chemotherapy (PRI- MA): a phase 3, randomised controlled trial. Lancet. 2011; 377:42-51. 25. Leonard JP, Trneny M, Offner F, et al. AUG- MENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lympho- ma. J Clin Oncol. 2019; 37:1188-1199. 26. Fowler NH, Nastoupil LJ, Chin C. et al. A Pha- se I/II Study of Lenalidomide Plus Obinutuzu- mab in Relapsed Indolent Lymphoma. Blood 2019; 134 (Supplement_1): 348. 27. Morschhauser F, Tilly H, Chaidos A, et al. Ta- zemetostat for patients with relapsed or re- fractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020; 21:1433-1442. 28. Zinzani PL, Flinn LW, Yuen SLS, et al. Vene- toclax-rituximab with or without bendamus- tine vs bendamustine-rituximab in relapsed/ refractory follicular lymphoma. Blood. 2020; 136:2628-2637. 29. Barlett NL, Costello BA, LaPlant BR, et al. Sin- gle-agent ibrutinib in relapsed or refractory follicular lymphoma: A phase 2 consortium trial. Blood. 2018; 131:182-190. 30. Fowler NH, Nastoupil L, De Vos S, et al. The combination of ibrutinib and rituximab de- monstrates activity in first-line follicular lymphoma. Br J Haematol. 2020; 189:650- 660. 31. Otham T, Rosenberg AS, Timmerman J, et al. A Phase II Trial of the Combination of Obi- nutuzumab, Venetoclax, and Ibrutinib in Pa- tients with Previously Untreated Follicular Lymphoma. Blood 2022; 140 (Supplement 1): 11954–11955. 32. Richardson NC, Kasamon Y, Pazdur R, et al. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol. 2022; 23:563-566. 33. Lopedote P, Shadman M. Targeted Treatment of Relapsed or Refractory Follicular Lympho- ma: Focus on the Therapeutic Potential of Mosunetuzumab. Cancer Manag Res. 2023; 15:257-264. 34. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refrac- tory follicular lymphoma: a single-arm, mul- ticentre, phase 2 study. Lancet Oncol. 2022; 23:1055-1065. 35. Barlett NL, Sehn LH, Matasar MJ, et al. Mo- sunetuzumab Monotherapy Demonstrates Du- rable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study. Blood 2022; 140 (Supplement 1): 1467–1470. 36. Bosch F, Kuruvilla J, Vassilakopoulos TP, et al. Indirect Treatment Comparisons of Mosunetu- zumab With Third-and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2024;24:105- 121. 37. Kim TM, Taszner M, Cho SG, et al. Odronex- tamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pi- votal Phase II Study ELM-2. Blood 2022; 140 (Supplement 1): 2280–2282. 38. Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in pa- tients with relapsed or refractory B-cell non- Hodgkin lymphoma: an open-label phase 1/2 study. Lancet. 2021; 398:1157-1169. 39. Jacobson CA, Chavez JC, Sehgal AR, et al. Axi- cabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022; 23:91-103. 40. Neelapu SS, Chavez JC, Sehgal AR, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non- Hodgkin lymphoma (ZUMA-5). Blood. 2024; 143:496-506. 41. Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refrac- tory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022; 28:325-332. 42. Jiménez-Ubieto A, Grande C, Caballero D et al. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Ri- tuximab Exposure. Biol Blood Marrow Trans- plant. 2017; 23:1631-1640. 43. Sureda A, Zhang MJ, Dreger P, et al. Alloge- neic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combi- ned analysis on behalf of the Lymphoma Wor- king Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018; 124:1733-1742. Si desea citar nuestro artículo: Fernández-Rañada de la Gándara JM. Linfoma no hodgkin foli- cular (LF) heterogeneidad, manejo y perspectivas. An RANM. 2025;142(01): 41– 50. DOI: 10.32440/ar.2025.142.01. rev04